Taxed on Losses: The $239M Bet Inside Cresco Labs (CRLBF)
Listen to this report
RoboSystems Initiating Coverage · Cresco Labs Inc. · CSE: CL / OTCQX: CRLBF · FY2025 40-F (filed March 6, 2026) + Q1 2026 results · Data read live from the RoboSystems SEC graph July 16, 2026 · Not investment advice; no price targets.
The Hook
Over the last three fiscal years, Cresco Labs lost a combined $252.9 million before taxes. Over those same three years, the IRS charged it $127.4 million in income tax expense. In fiscal 2025 alone the company posted a $95.4 million pretax loss and still booked $44.6 million of tax - an effective tax rate of negative 46.8 percent. In fiscal 2024 the rate was negative 470 percent. That is not an accounting error. It is Section 280E, the tax code written for drug traffickers, applied to a company running 77 licensed dispensaries and the number-one branded cannabis portfolio in America.
Here is the part almost nobody prices: Cresco largely stopped paying the disputed portion. Its reserve for unrecognized tax benefits - the formal IOU it would owe if the IRS wins - went from $18.8 million at the end of 2023 to $200.5 million at the end of 2024 to $238.9 million at the end of 2025, growing about $47 million a year plus $10.3 million of accrued penalties and interest in 2025 alone. At roughly $0.77 a share, Cresco's fully diluted market cap is about $390 million. The disputed tax bill is now over 60 percent of the entire market cap. This stock has become one of the most leveraged bets in the sector on how the 280E endgame plays out - and the endgame is live: the DEA's hearing on rescheduling all marijuana concluded July 15, 2026, one day before this report.
Company Snapshot
Cresco Labs is a Chicago-headquartered multi-state operator - the self-styled "CPG company of cannabis." It runs 12 production sites and 77 retail locations (as of March 31, 2026) across nine states: Florida (31 stores), Pennsylvania (18, plus 9 more under a management services agreement - 27 total), Illinois (10), Ohio (8), Massachusetts (4), New York (3), plus cultivation ramping in Kentucky and a newly awarded Texas license. It holds the #1 branded share position in multiple billion-dollar markets - Illinois, Pennsylvania, Massachusetts - behind brands like Cresco, High Supply, FloraCal, Good News and Mindy's, and its Sunnyside dispensaries generate roughly 30 percent more revenue per store than the average store across its footprint. FY2025 revenue split: $433 million retail (66 percent), $223 million third-party wholesale (34 percent). Management pegs roughly half of revenue as medical. Primary filing: FY2025 Form 40-F (Canadian MJDS filer, calendar year ended December 31, 2025), newly queryable in XBRL - this is RoboSystems' first coverage of the name.
The Financial Story
The top line has fallen three straight years - by design, partly. Revenue went $842.7 million (FY2022) → $770.9 million (FY2023) → $724.3 million (FY2024) → $655.8 million (FY2025), all per the SEC graph - down 22 percent from the 2022 peak. Some of that is strategy: Cresco exited California (selling Sonoma's Finest) and absorbed Michigan's new excise-tax disruption (Michigan is now under 3 percent of the business). Most of it is the sector-wide story: wholesale price deflation in mature markets, with Illinois - Cresco's home market - down 12.5 percent in dollar terms in 2025 even as unit volume rose. Q1 2026 revenue of $151.3 million (down 8.7 percent year over year) is, per management, the "baseline" quarter; they guided Q2 up approximately 10 percent sequentially on the new Pennsylvania and Ohio stores, with low-single-digit organic growth underneath.
Against that shrinking top line, the margin discipline is real - and best-in-class. Adjusted gross margin was 50.2 percent in FY2025 and 50.7 percent in Q1 2026; adjusted EBITDA was $157 million in FY2025 at a 24.0 percent margin - sector-leading efficiency for a company this size - and $33 million (21.7 percent) in the seasonally slow Q1. Adjusted SG&A is down to 33.7 percent of revenue. The engine is cultivation yield gains, retail productivity, and a lean cost structure management says converts incremental gross profit to EBITDA at a high rate. This is the angle on Cresco: it is running the sector's most disciplined P&L above the tax line, while the tax line and the balance sheet tell a much darker story.
GAAP earnings and cash flow have diverged - read both. The FY2025 net loss of $140.0 million includes $105.1 million of non-cash impairments ($75.3 million of it goodwill), mostly writing down the New York reporting unit and marking the California exit. Meanwhile operating cash flow was positive $72.9 million and free cash flow positive $38 million. But be honest about a nuance most coverage misses: part of that operating cash flow exists because Cresco is not paying the disputed 280E taxes - the unrecognized-tax-benefit reserve grew ~$47 million in 2025, which is cash the IRS says it is owed but hasn't collected. Adjust for that and the underlying free cash flow is roughly break-even. Cumulative impairments since the boom: $151.0 million in FY2023 plus $105.1 million in FY2025 - more than a quarter billion dollars of boom-era value written off, leaving $208 million of goodwill and $288 million of intangibles (about 41 percent of total assets) still on the books.
The balance sheet is the bear case. As of March 31, 2026: $10.9 million short-term debt, $418.2 million long-term debt, $144.7 million of long-term leases - $573.8 million total obligations against $66.8 million of cash, for net debt of $507 million. The anchor is a $325 million senior secured term loan refinanced in August 2025 at 12.5 percent, due 2030. Cash interest paid in FY2025 was $51.3 million - nearly 8 cents of every revenue dollar goes to lenders before anything else. Stack the $239 million disputed tax reserve on top and the enterprise carries roughly $750 million of hard claims senior to a $390 million equity ticket. That is why Cresco trades at 40 percent of its 52-week high while Tier-1 peers average near 70 percent: same sector, more torque.
Catalyst Scenarios - How the Math Changes
280E relief, medical slice - firing now. The April 28, 2026 partial rescheduling moved state-licensed medical marijuana to Schedule III, and Treasury's transition rule effectively removes 280E from qualifying medical activity back to January 1, 2026 for calendar-year filers. Roughly 50 percent of Cresco's revenue is medical (CFO Sharon Schuler, Q1 call - she cautioned revenue mix is not a clean proxy for the tax benefit, since the relief follows expense apportionment). Directionally: Cresco booked $44.6 million of tax expense in FY2025 against what a normal 21 percent regime would have made a $20 million benefit - a ~$65 million annual swing at the extreme. Even if only the medical half qualifies near-term, that is plausibly $20-30 million a year of earnings and, eventually, cash that stops leaving the building. Watch the Q2 report (August 6) for the first quarter where the accounting shows it.
Broad rescheduling - the big one, and it just went to the judge. The DEA's expedited hearing on rescheduling all marijuana ran June 29 through July 15, 2026. Notably, the opposition's own expert acknowledged under cross-examination that cannabis meets the statutory Schedule III criteria. Next: post-hearing briefs, a recommended decision from the chief administrative law judge, then the DEA Administrator's final rule - no date certain. Because 280E keys off the drug's schedule, not the legality of the sale, a broad Schedule III order lifts 280E from Cresco's adult-use half too - without making recreational sales federally legal. Full relief on FY2025's run rate turns a company that books ~$45 million of annual tax expense on losses into one that would have booked a benefit. Pro forma on FY2025 numbers: $157 million adjusted EBITDA, less ~$48 million D&A, less ~$58 million net interest, taxed at 21-25 percent, yields roughly $38-40 million of normalized net income - about 10 times adjusted earnings at today's $0.77 (call it 10 to 16 times if you insist on expensing the ~$20 million of stock comp). For a Tier-1 MSO, that is a single-digit multiple on normalized earnings.
The back-tax overhang cuts the other way - and it's the swing factor. Prospective relief does not erase the $238.9 million already reserved. The IRS is actively fighting the "rescheduling gambit" (it sued TerrAscend in May to claw back an $8.3 million refund; aggregate MSO exposure is ~$1.6 billion), there is no amnesty program, and interest compounds daily. The filing's own disclosure flags up to $73 million of the reserve as reasonably possible to resolve within twelve months. A full IRS win means a nine-figure cash claim against a company with $67 million of cash; a favorable resolution (or a broad order that strengthens settlement leverage) releases a reserve worth over 60 percent of the market cap. No other Tier-1 name has this ratio.
Growth optionality is unusually cheap. Pennsylvania - where Cresco is the #1 wholesaler and now a 27-store retailer, the state's largest footprint - remains medical-only; adult-use stalled again in the 2026 budget, but a flip (realistically 2027+) lands on a business already built for it. Kentucky had its first harvest in April; Texas awarded Cresco one of only 15 vertically integrated medical licenses in a state of 31 million people. And the November 2026 federal hemp ban should channel intoxicating-hemp demand into licensed dispensaries precisely in states like Illinois - which passed dispensary-channeling legislation - where Cresco is the incumbent share leader. (Honest counterpoint: Whitney Economics found hemp bans alone did not measurably lift marijuana sales in ban-only states; the benefit is real mainly where the state channels demand, as Illinois does.) None of this appears priced at 1.3 times revenue.
Valuation - What It's Worth If It's a Normal Business
Two lenses, all figures implied values under stated assumptions - not targets. Today: ~$0.77 (July 16, 2026), ~505 million fully diluted shares, ~$390 million market cap, ~$0.90 billion enterprise value including leases - about 5.7 times FY2025 adjusted EBITDA (SSC comps had CRLBF at 5.4x on May 29; Tier-1 average 4.7x, Verano 3.3x, Green Thumb 5.3x).
Scenario DCF (levered, simplified). Base case - 280E persists on adult-use, medical relief holds, back taxes enforced over time: ~$140 million 2026E adjusted EBITDA, $35 million capex, $51 million cash interest, $25 million cash taxes leaves ~$30 million of levered free cash flow; at an 18-20 percent equity discount rate and 2-3 percent growth, implied equity is roughly $0.25-0.50 per share (a full, accelerated IRS collection scenario is worse). Broad-rescheduling case - adult-use relief from 2027, cash taxes normalize, modest growth from PA/KY/TX and hemp migration, and refinancing the 12.5 percent debt a few hundred basis points cheaper as capital access opens: levered FCF builds toward $60 million, implying roughly $0.70-1.10 per share. Elevated discount rates are deliberate: this is an OTC-listed, partially Schedule I business.
Cross-sector re-rating. CPG and wellness comparables (Constellation ~12x EV/EBITDA; the campaign comp set runs ~10-14x) applied to Cresco's $157 million of EBITDA imply a $1.6-2.2 billion enterprise value; net of $507 million of net debt that is roughly $2.10-3.35 per share - before the back-tax reserve (about $0.47 per share if paid in full), so call the honest normalized band $1.60-2.90.
What today's price implies: at $0.77 the market is paying for something between the base case and the broad-order case - meaningful probability on broad rescheduling, near-zero credit for a CPG-style re-rate, and a heavy haircut for the $239 million reserve and the 12.5 percent debt stack. The equity is priced as an option; the hearing record just went to the judge.
Risks and Open Questions
The bear case is concrete. The D.C. Circuit stay motion against the partial order was still undecided as of mid-July (DOJ filed its opposition July 2); a stay or vacatur removes the Schedule III predicate and could force operators to resume accruing - an earnings and credibility whipsaw. The broad order could stall in post-hearing process or litigation for quarters. The IRS is winning the retroactivity fight so far (~40 straight 280E challenges lost; the TerrAscend clawback; Mission Organic upholding offer-in-compromise rejections), and Cresco's $239 million reserve accrues penalties and interest daily. Ohio's attorney general named Cresco among nine MSOs in a price-fixing antitrust suit (February 2026) - unresolved. Wholesale deflation in Illinois has not stopped. Pennsylvania adult-use is a 2027-plus hope, not a plan. A Teamsters strike hit its Pennsylvania operations this spring - integration of the nine PA stores (still awaiting regulatory close, expected around end of Q2) is not riskless. And $573.8 million of total obligations against $67 million of cash leaves little room for a macro stumble; Q1 free cash flow was negative $13.2 million (seasonal, but real).
The Bottom Line
Operationally, Cresco is doing exactly what a disciplined operator should do in a deflating market: defend share, expand margins, buy growth cheaply in the states that matter. That discipline produced the sector's best margin stack on a shrinking top line. What the stock is actually pricing, though, is the tax endgame: a $239 million disputed IOU and $45 million a year of phantom tax expense on one side; medical relief already flowing, a broad Schedule III record now in front of the DEA's judge, and roughly 10-times normalized earnings on the other. Watch four things: the ALJ's recommended decision and the DEA Administrator's final rule; the D.C. Circuit stay; the Q2 report on August 6 (first clean look at medical 280E relief and the PA stores); and any movement - either way - on the unrecognized-tax-benefit reserve. The framework is here; the decision is yours.
Built with RoboSystems - structured SEC filing data for every public company, straight from the XBRL. Set it up in about five minutes at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.